RE
ARCT icon

RBC Europe’s Arcturus Therapeutics ARCT Stock Holding History

RBC Europe’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-73
Closed -$3.49K – 660
2021
Q3 		$3.49K Hold
73
– – ﹤0.01% 1077
2021
Q2 		$2.47K Hold
73
– – ﹤0.01% 1104
2021
Q1 		$3.02K Buy
+73
New +$4.35K ﹤0.01% 1043

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RBC Europe's ARCT Position: Q4 2021 in Review

RBC Europe sold out of Arcturus Therapeutics (ARCT) in Q4 2021, closing a stake of 73 shares — an estimated $3.49K sold.

RBC Europe first reported a position in ARCT in Q1 2021 and held it in 3 quarters. The position peaked at $3.49K in Q3 2021. 139 funds tracked by Wall St. Rank hold ARCT as of Q4 2021.

  • RBC Europe reported no remaining Arcturus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 73 Arcturus Therapeutics shares in Q4 2021, an estimated $3.49K.
  • RBC Europe first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 3 quarters.
  • RBC Europe's Arcturus Therapeutics position peaked at $3.49K in Q3 2021.
  • 139 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.